glp-1 triple agonist PDB-101: Molecule of the Month: Receptor Agonists Trends in the Development of

In 2002, Eli Lilly & Company entered into a partnership with Amylin Pharmaceuticals worth $325 million for the rights to exenatide

After two years (120 weeks), the patients retained roughly one-third of their original weight loss (5.6% of the original 17.3% loss)

doi:10.1007/s00125-010-1896-4 29

doi: 10.2337/db10-0103 66 SaundersALBodineCSnell-BergeonJForlenzaGPShahVN

Recommendations for the peri-operative management of patients taking sodium-glucose cotransporter-2 inhibitors [1] : The risk of peri-operative ketoacidosis and mitigation strategies should be discussed with the patient using a shared decision-making approach." "Sodium-glucose cotransporter-2 inhibitors should be omitted the day before and the day of a procedure

However, it is uncertain if the metabolic benefits of GLP-1 RAs used prior to pregnancy are sustained in pregnancy or if these benefits lead to improved pregnancy outcomes